Sanwa licenses DPP-4 inhibitor to Choongwae
This article was originally published in Scrip
Executive Summary
Sanwa Kagaku Kenkyusho has licensed its pipeline DPP-4 inhibitor antidiabetic SK-0403 to Choongwae Pharma for development and commercialisation in South Korea. The Japanese firm, which is part of the Japanese pharmaceutical wholesaling group Suzuken, will receive undisclosed up-front, milestone and sales-based royalties as part of the deal. SK-0403 is currently in Phase II development in Japan, where it has just been licensed to Kowa for joint development and commercialisation.